151 related articles for article (PubMed ID: 38398204)
1. Cost-Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model.
Lai CH; Shi HY; Tsai CE; Yang YC; Chiu SF
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398204
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
Tian F; Houle SKD; Alsabbagh MW; Wong WWL
Pharmacoeconomics; 2020 Feb; 38(2):181-192. PubMed ID: 31691902
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
[TBL] [Abstract][Full Text] [Related]
4. Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia.
Sanai FM; Aljawad M; Alghamdi AS; Yehoshua A; Khathlan A; Alghamdi M; Kozma S; Smith N; El-Moustaid F; Jeyakumar S; Kachru N
Saudi J Gastroenterol; 2024 Jan; 30(1):23-29. PubMed ID: 37417192
[TBL] [Abstract][Full Text] [Related]
5. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
6. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir.
Yuan GC; Chen AZ; Wang WX; Yi XL; Tu L; Peng F; Qiu ZH
World J Clin Cases; 2023 Dec; 11(34):8139-8146. PubMed ID: 38130795
[TBL] [Abstract][Full Text] [Related]
8. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.
Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 May; 42(5):1017-1026. PubMed ID: 35220649
[TBL] [Abstract][Full Text] [Related]
9. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapy from entecavir to tenofovir alafenamide
Itokawa N; Atsukawa M; Tsubota A; Takaguchi K; Nakamuta M; Hiraoka A; Kato K; Abe H; Mikami S; Shimada N; Chuma M; Akito N; Uojima H; Ogawa C; Asano T; Tani J; Morishita A; Senoh T; Yamashita N; Oikawa T; Matsumoto Y; Koeda M; Yoshida Y; Tanabe T; Okubo T; Arai T; Hayama K; Iwashita AN; Kondo C; Tada T; Toyoda H; Kumada T; Iwakiri K
JGH Open; 2021 Jan; 5(1):34-40. PubMed ID: 33490611
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis.
Ma X; Liu S; Wang M; Wang Y; Du S; Xin Y; Xuan S
J Clin Transl Hepatol; 2021 Jun; 9(3):335-344. PubMed ID: 34221919
[TBL] [Abstract][Full Text] [Related]
12. Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Kumada T; Toyoda H; Yasuda S; Ito T; Tanaka J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e898-e904. PubMed ID: 35048656
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
15. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients.
Lai RM; Lin S; Wang MM; Li N; Zhou JH; Lin XY; Chen TB; Zhu YY; Zheng Q
World J Hepatol; 2023 Aug; 15(8):964-972. PubMed ID: 37701915
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study.
Hagiwara S; Nishida N; Ueshima K; Yoshida A; Minami Y; Kudo M
Hepatol Res; 2021 Jul; 51(7):767-774. PubMed ID: 33900663
[TBL] [Abstract][Full Text] [Related]
17. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
18. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Li ZB; Li L; Niu XX; Chen SH; Fu YM; Wang CY; Liu Y; Shao Q; Chen G; Ji D
Liver Int; 2021 Jun; 41(6):1254-1264. PubMed ID: 33404182
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection.
Kim SH; Cho EJ; Jang BO; Lee K; Choi JK; Choi GH; Lee JH; Yu SJ; Kim YJ; Lee YB; Yoon JH; Kim JW; Jeong SH; Jang ES
Liver Int; 2022 Feb; 42(2):320-329. PubMed ID: 34679254
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
Dai Z; Wong IOL; Xie C; Xu W; Xiang Y; Peng L; Lau EHY
Clin Microbiol Infect; 2022 Feb; 28(2):300.e1-300.e8. PubMed ID: 34197929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
